Anika Therapeutics (ANIK) Tops Q3 EPS by 12c

Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.59, $0.12 better than the analyst estimate of $0.47. Revenue for the quarter came in at $25.8 million versus the consensus estimate of $26.6 million.

"We continued to deliver solid financial results in the third quarter, while expanding globally and advancing our deep and differentiated pipeline to drive sustained growth,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “Last quarter, we had a productive meeting with the FDA regarding the CINGAL regulatory submission and continue to gain alignment on additional clinical and non-clinical work required to bring this important treatment to the U.S. Our confidence in the future success of CINGAL in the U.S. has been reaffirmed by how well CINGAL has been received by physicians in Canada and Europe, where we recently launched. We are well-positioned to achieve our operational and financial objectives for 2016 and to create significant near- and long-term value for patients and shareholders.”

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Artisan Partners Asset Management (APAM) Misses Q1 EPS by 1c
• Visa (V) Tops Q2 EPS by 7c, offers guidance